Induced Pluripotent Stem Cell (iPSC)
Global Induced Pluripotent Stem Cell ((iPSC) Market to Reach $3.1 Billion by 2030
In the changed post COVID-19 business landscape, the global market for Induced Pluripotent Stem Cell ((iPSC) estimated at US$1.8 Billion in the year 2022, is projected to reach a revised size of US$3.1 Billion by 2030, growing at aCAGR of 6.9% over the period 2022-2030. Vascular Cells, one of the segments analyzed in the report, is projected to record 7.4% CAGR and reach US$1 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Cardiac Cells segment is readjusted to a revised 8.1% CAGR for the next 8-year period.
The U.S. Market is Estimated at $820.4 Million, While China is Forecast to Grow at 8.8% CAGR
The Induced Pluripotent Stem Cell ((iPSC) market in the U.S. is estimated at US$820.4 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$116.8 Million by the year 2030 trailing a CAGR of 8.8% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.7% and 7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 6.7% CAGR.
Select Competitors (Total 51 Featured) -
- Lonza Group Ltd.
- Evotec SE
- FUJIFILM Holdings Corporation
- Abcam PLC
- Horizon Discovery Ltd.
- Cell Signaling Technology, Inc.
- Cell Applications, Inc.
- Invivogen
- ALSTEM, LLC
- Censo Biotechnologies Ltd.
- Creative Bioarray
- Creative Biolabs
- Axol Bioscience Ltd.
- ID Pharma Co., Ltd.
- BlueRock Therapeutics, LLC
The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.
Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
- I. METHODOLOGY
- II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- Impact of Covid-19 and a Looming Global Recession
- Induced Pluripotent Stem Cells (iPSCs) Market Gains from Increasing Use in Research for COVID-19
- Studies Employing iPSCs in COVID-19 Research
- Stem Cells, Application Areas, and the Different Types: A Prelude
- Applications of Stem Cells
- Types of Stem Cells
- Induced Pluripotent Stem Cell (iPSC): An Introduction
- Production of iPSCs
- First & Second Generation Mouse iPSCs
- Human iPSCs
- Key Properties of iPSCs
- Transcription Factors Involved in Generation of iPSCs
- Noteworthy Research & Application Areas for iPSCs
- Induced Pluripotent Stem Cell ((iPSC) Market: Growth Prospects and Outlook
- Drug Development Application to Witness Considerable Growth
- Technical Breakthroughs, Advances & Clinical Trials to Spur Growth of iPSC Market
- North America Dominates Global iPSC Market
- Competition
- Recent Market Activity
- Select Innovation/Advancement
- Induced Pluripotent Stem Cell (iPSC) – Global Key Competitors Percentage Market Share in 2021 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2021 (E)
- 2. FOCUS ON SELECT PLAYERS
- Axol Bioscience Ltd. (UK)
- Cynata Therapeutics Limited (Australia)
- Evotec SE (Germany)
- Fate Therapeutics, Inc. (USA)
- FUJIFILM Cellular Dynamics, Inc. (USA)
- Ncardia (Belgium)
- Pluricell Biotech (Brazil)
- REPROCELL USA, Inc. (USA)
- Sumitomo Dainippon Pharma Co., Ltd. (Japan)
- Takara Bio, Inc. (Japan)
- Thermo Fisher Scientific, Inc. (USA)
- ViaCyte, Inc. (USA)
- 3. MARKET TRENDS & DRIVERS
- Effective Research Programs Hold Key in Roll Out of Advanced iPSC Treatments
- Induced Pluripotent Stem Cells: A Giant Leap in the Therapeutic Applications
- Research Trends in Induced Pluripotent Stem Cell Space
- Worldwide Publication of hESC and hiPSC Research Papers for the Period 2008-2010, 2011-2013 and 2014-2016
- Number of Original Research Papers on hESC and iPSC Published Worldwide (2014-2016)
- Concerns Related to Embryonic Stem Cells Shift the Focus onto iPSCs
- Regenerative Medicine: A Promising Application of iPSCs
- Induced Pluripotent: A Potential Competitor to hESCs?
- Global Regenerative Medicine Market Size in US$ Billion for 2019, 2021, 2023 and 2025
- Global Stem Cell & Regenerative Medicine Market by Product (in %) for the Year 2019
- Global Regenerative Medicines Market by Category: Breakdown (in %) for Biomaterials, Stem Cell Therapies and Tissue Engineering for 2019
- Pluripotent Stem Cells Hold Significance for Cardiovascular Regenerative Medicine
- Leading Causes of Mortality Worldwide: Number of Deaths in Millions & % Share of Deaths by Cause for 2017
- Leading Causes of Mortality for Low-Income and High-Income Countries
- Growing Importance of iPSCs in Personalized Drug Discovery
- Persistent Advancements in Genetics Space and Subsequent Growth in Precision Medicine Augur Well for iPSCs Market
- Global Precision Medicine Market (In US$ Billion) for the Years 2018, 2021 & 2024
- Increasing Prevalence of Chronic Disorders Supports Growth of iPSCs Market
- Worldwide Cancer Incidence: Number of New Cancer Cases Diagnosed for 2012, 2018 & 2040
- Number of New Cancer Cases Reported (in Thousands) by Cancer Type: 2018
- Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
- Rising Diabetes Prevalence Presents Opportunity for iPSCs Market: Number of Adults (20-79) with Diabetes (in Millions) by Region for 2017 and 2045
- Aging Demographics Add to the Global Burden of Chronic Diseases, Presenting Opportunities for iPSCs Market
- Expanding Elderly Population Worldwide: Breakdown of Number of People Aged 65+ Years in Million by Geographic Region for the Years 2019 and 2030
- Growth in Number of Genomics Projects Propels Market Growth
- Genomic Initiatives in Select Countries
- New Gene-Editing Tools Spur Interest and Investments in Genetics, Driving Lucrative Growth Opportunities for iPSCs: Total VC Funding (In US$ Million) in Genetics for the Years 2014, 2015, 2016, 2017 and 2018
- Launch of Numerous iPSCs-Related Clinical Trials Set to Benefit Market Growth
- Number of Induced Pluripotent Stem Cells based Studies by Select Condition: As on Oct 31, 2020
- iPSCs-based Clinical Trial for Heart Diseases
- Induced Pluripotent Stem Cells for Stroke Treatment
- ‘Off-the-shelf’ Stem Cell Treatment for Cancer Enters Clinical Trial
- iPSCs for Hematological Disorders
- Market Benefits from Growing Funding for iPSCs-Related R&D Initiatives
- Stem Cell Research Funding in the US (in US$ Million) for the Years 2016 through 2021
- Human iPSC Banks: A Review of Emerging Opportunities and Drawbacks
- Human iPSC Banks Worldwide: An Overview
- Cell Sources and Reprogramming Methods Used by Select iPSC Banks
- Innovations, Research Studies & Advancements in iPSCs
- Key iPSC Research Breakthroughs for Regenerative Medicine
- Researchers Develop Novel Oncogene-Free and Virus-Free iPSC Production Method
- Scientists Study Concerns of Genetic Mutations in iPSCs
- iPSCs Hold Tremendous Potential in Transforming Research Efforts
- Researchers Highlight Potential Use of iPSCs for Developing Novel Cancer Vaccines
- Scientists Use Machine Learning to Improve Reliability of iPSC Self-Organization
- STEMCELL Technologies Unveils mTeSR™ Plus
- Challenges and Risks Related to Pluripotent Stem Cells
- A Glance at Issues Related to Reprogramming of Adult Cells to iPSCs
- A Note on Legal, Social and Ethical Considerations with iPSCs
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Recent Past, Current & Future Analysis for Vascular Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
- TABLE 2: World 8-Year Perspective for Vascular Cells by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- TABLE 3: World Recent Past, Current & Future Analysis for Cardiac Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
- TABLE 4: World 8-Year Perspective for Cardiac Cells by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- TABLE 5: World Recent Past, Current & Future Analysis for Neuronal Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
- TABLE 6: World 8-Year Perspective for Neuronal Cells by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- TABLE 7: World Recent Past, Current & Future Analysis for Liver Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
- TABLE 8: World 8-Year Perspective for Liver Cells by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- TABLE 9: World Recent Past, Current & Future Analysis for Immune Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
- TABLE 10: World 8-Year Perspective for Immune Cells by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- TABLE 11: World Recent Past, Current & Future Analysis for Other Cell Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
- TABLE 12: World 8-Year Perspective for Other Cell Types by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- TABLE 13: World Recent Past, Current & Future Analysis for Cellular Reprogramming by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
- TABLE 14: World 8-Year Perspective for Cellular Reprogramming by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- TABLE 15: World Recent Past, Current & Future Analysis for Cell Culture by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
- TABLE 16: World 8-Year Perspective for Cell Culture by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- TABLE 17: World Recent Past, Current & Future Analysis for Cell Differentiation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
- TABLE 18: World 8-Year Perspective for Cell Differentiation by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- TABLE 19: World Recent Past, Current & Future Analysis for Cell Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
- TABLE 20: World 8-Year Perspective for Cell Analysis by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- TABLE 21: World Recent Past, Current & Future Analysis for Cellular Engineering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
- TABLE 22: World 8-Year Perspective for Cellular Engineering by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- TABLE 23: World Recent Past, Current & Future Analysis for Other Research Methods by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
- TABLE 24: World 8-Year Perspective for Other Research Methods by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- TABLE 25: World Recent Past, Current & Future Analysis for Drug Development & Toxicology Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
- TABLE 26: World 8-Year Perspective for Drug Development & Toxicology Testing by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- TABLE 27: World Recent Past, Current & Future Analysis for Academic Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
- TABLE 28: World 8-Year Perspective for Academic Research by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- TABLE 29: World Recent Past, Current & Future Analysis for Regenerative Medicine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
- TABLE 30: World 8-Year Perspective for Regenerative Medicine by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- TABLE 31: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
- TABLE 32: World 8-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- TABLE 33: World Induced Pluripotent Stem Cell (iPSC) Market Analysis of Annual Sales in US$ Thousand for Years 2020 through 2030
- TABLE 34: World Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
- TABLE 35: World 8-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2023 & 2030
- III. MARKET ANALYSIS
- UNITED STATES
- Induced Pluripotent Stem Cell (iPSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
- TABLE 36: USA Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Cell Type - Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 37: USA 8-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Cell Type - Percentage Breakdown of Value Revenues for Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types for the Years 2023 & 2030
- TABLE 38: USA Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Research Method - Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 39: USA 8-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Research Method - Percentage Breakdown of Value Revenues for Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods for the Years 2023 & 2030
- TABLE 40: USA Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Application - Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 41: USA 8-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Application - Percentage Breakdown of Value Revenues for Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine and Other Applications for the Years 2023 & 2030
- CANADA
- TABLE 42: Canada Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Cell Type - Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 43: Canada 8-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Cell Type - Percentage Breakdown of Value Revenues for Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types for the Years 2023 & 2030
- TABLE 44: Canada Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Research Method - Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 45: Canada 8-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Research Method - Percentage Breakdown of Value Revenues for Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods for the Years 2023 & 2030
- TABLE 46: Canada Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Application - Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 47: Canada 8-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Application - Percentage Breakdown of Value Revenues for Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine and Other Applications for the Years 2023 & 2030
- JAPAN
- Induced Pluripotent Stem Cell (iPSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
- TABLE 48: Japan Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Cell Type - Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 49: Japan 8-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Cell Type - Percentage Breakdown of Value Revenues for Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types for the Years 2023 & 2030
- TABLE 50: Japan Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Research Method - Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 51: Japan 8-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Research Method - Percentage Breakdown of Value Revenues for Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods for the Years 2023 & 2030
- TABLE 52: Japan Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Application - Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 53: Japan 8-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Application - Percentage Breakdown of Value Revenues for Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine and Other Applications for the Years 2023 & 2030
- CHINA
- Induced Pluripotent Stem Cell (iPSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
- TABLE 54: China Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Cell Type - Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 55: China 8-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Cell Type - Percentage Breakdown of Value Revenues for Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types for the Years 2023 & 2030
- TABLE 56: China Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Research Method - Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 57: China 8-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Research Method - Percentage Breakdown of Value Revenues for Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods for the Years 2023 & 2030
- TABLE 58: China Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Application - Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 59: China 8-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Application - Percentage Breakdown of Value Revenues for Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine and Other Applications for the Years 2023 & 2030
- EUROPE
- Induced Pluripotent Stem Cell (iPSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
- TABLE 60: Europe Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Cell Type - Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 61: Europe 8-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Cell Type - Percentage Breakdown of Value Revenues for Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types for the Years 2023 & 2030
- TABLE 62: Europe Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Research Method - Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 63: Europe 8-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Research Method - Percentage Breakdown of Value Revenues for Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods for the Years 2023 & 2030
- TABLE 64: Europe Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Application - Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 65: Europe 8-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Application - Percentage Breakdown of Value Revenues for Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine and Other Applications for the Years 2023 & 2030
- TABLE 66: Europe Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
- TABLE 67: Europe 8-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2023 & 2030
- FRANCE
- Induced Pluripotent Stem Cell (iPSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
- TABLE 68: France Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Cell Type - Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 69: France 8-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Cell Type - Percentage Breakdown of Value Revenues for Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types for the Years 2023 & 2030
- TABLE 70: France Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Research Method - Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 71: France 8-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Research Method - Percentage Breakdown of Value Revenues for Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods for the Years 2023 & 2030
- TABLE 72: France Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Application - Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 73: France 8-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Application - Percentage Breakdown of Value Revenues for Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine and Other Applications for the Years 2023 & 2030
- GERMANY
- Induced Pluripotent Stem Cell (iPSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
- TABLE 74: Germany Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Cell Type - Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 75: Germany 8-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Cell Type - Percentage Breakdown of Value Revenues for Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types for the Years 2023 & 2030
- TABLE 76: Germany Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Research Method - Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 77: Germany 8-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Research Method - Percentage Breakdown of Value Revenues for Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods for the Years 2023 & 2030
- TABLE 78: Germany Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Application - Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 79: Germany 8-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Application - Percentage Breakdown of Value Revenues for Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine and Other Applications for the Years 2023 & 2030
- ITALY
- TABLE 80: Italy Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Cell Type - Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 81: Italy 8-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Cell Type - Percentage Breakdown of Value Revenues for Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types for the Years 2023 & 2030
- TABLE 82: Italy Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Research Method - Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 83: Italy 8-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Research Method - Percentage Breakdown of Value Revenues for Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods for the Years 2023 & 2030
- TABLE 84: Italy Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Application - Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 85: Italy 8-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Application - Percentage Breakdown of Value Revenues for Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine and Other Applications for the Years 2023 & 2030
- UNITED KINGDOM
- Induced Pluripotent Stem Cell (iPSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
- TABLE 86: UK Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Cell Type - Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 87: UK 8-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Cell Type - Percentage Breakdown of Value Revenues for Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types for the Years 2023 & 2030
- TABLE 88: UK Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Research Method - Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 89: UK 8-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Research Method - Percentage Breakdown of Value Revenues for Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods for the Years 2023 & 2030
- TABLE 90: UK Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Application - Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 91: UK 8-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Application - Percentage Breakdown of Value Revenues for Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine and Other Applications for the Years 2023 & 2030
- REST OF EUROPE
- TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Cell Type - Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 93: Rest of Europe 8-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Cell Type - Percentage Breakdown of Value Revenues for Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types for the Years 2023 & 2030
- TABLE 94: Rest of Europe Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Research Method - Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 95: Rest of Europe 8-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Research Method - Percentage Breakdown of Value Revenues for Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods for the Years 2023 & 2030
- TABLE 96: Rest of Europe Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Application - Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 97: Rest of Europe 8-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Application - Percentage Breakdown of Value Revenues for Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine and Other Applications for the Years 2023 & 2030
- ASIA-PACIFIC
- Induced Pluripotent Stem Cell (iPSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
- TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Cell Type - Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 99: Asia-Pacific 8-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Cell Type - Percentage Breakdown of Value Revenues for Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types for the Years 2023 & 2030
- TABLE 100: Asia-Pacific Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Research Method - Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 101: Asia-Pacific 8-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Research Method - Percentage Breakdown of Value Revenues for Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods for the Years 2023 & 2030
- TABLE 102: Asia-Pacific Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Application - Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 103: Asia-Pacific 8-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Application - Percentage Breakdown of Value Revenues for Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine and Other Applications for the Years 2023 & 2030
- REST OF WORLD
- TABLE 104: Rest of World Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Cell Type - Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 105: Rest of World 8-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Cell Type - Percentage Breakdown of Value Revenues for Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types for the Years 2023 & 2030
- TABLE 106: Rest of World Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Research Method - Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 107: Rest of World 8-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Research Method - Percentage Breakdown of Value Revenues for Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods for the Years 2023 & 2030
- TABLE 108: Rest of World Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Application - Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 109: Rest of World 8-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Application - Percentage Breakdown of Value Revenues for Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine and Other Applications for the Years 2023 & 2030
- IV. COMPETITION
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook